Bone-marrow vs adipose-derived stem cells: what's the difference, and which does Cheongdam Cell Clinic use?

Choosing the harvest source is one of the first questions patients should ask before deciding on treatment, since each source differs in collection method, cell yield and typical use. The two dominant sources in regenerative medicine are bone marrow and adipose (fat) tissue. Both are autologous — from the patient's own body — so neither raises the immune-compatibility concerns of donor cells.

Bone marrow is typically harvested from the iliac crest (hip bone) under local anaesthesia or light sedation, using a needle to aspirate a sample; this can cause brief discomfort and occasional soreness at the site. Fat is usually collected via mini-liposuction from the abdomen or thighs — a procedure many patients find more familiar since it resembles cosmetic liposuction.

In terms of yield, adipose tissue generally produces more stem cells per gram than bone marrow, which is why some clinics favour fat when cell quantity is the priority. Bone marrow's advantage lies in its far longer clinical research history, having been used to treat blood disorders and leukaemia long before 'stem cells for beauty or anti-ageing' became a familiar phrase.

Biologically, bone-marrow MSCs have a closer relationship with the blood and immune system, since bone marrow is where all blood cell types originate; research often cites bone-marrow MSCs for immune modulation and stimulating new blood vessel growth (angiogenesis). Adipose MSCs, meanwhile, are widely studied for soft-tissue and skin repair. Direct head-to-head human comparisons between the two sources remain limited.

Cheongdam Cell Clinic states it uses bone-marrow-derived stem cells across every programme — the whole-body rejuvenation programme (淸Cell), the sexual function programme (性Cell), the skin and hair programmes (美Cell, 毛Cell) and the pain programme (活Cell) — citing the immune and vascular link as its main rationale. Harvest, isolation and re-injection all take place within the same half-day, as the clinic describes it.

Patients comparing clinics should note that each provider may choose its cell source for different reasons — some prioritise the convenience of fat harvesting, others the immune-system link of bone marrow. There is no single 'better' answer; it depends on the treatment goal, the patient's condition and the evidence base for each specific indication.

Another consideration is the pain and recovery time for each harvesting method. Bone marrow aspiration can cause a dull ache around the hip for a day or two, while liposuction can leave bruising or swelling at the site, similar to standard liposuction. Both are considered low-risk when performed by an experienced physician, but patients should ask the clinic directly about post-procedure care.

In summary, both bone marrow and fat are widely used autologous stem cell sources, and there is no definitive academic consensus that one outperforms the other across every indication. What matters is understanding why a given clinic chose its source and asking for full details on cell yield, extraction method and the specific risks of each approach before deciding.